Cargando…

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. This is best highlighted by the sig...

Descripción completa

Detalles Bibliográficos
Autores principales: McGonagle, Dennis G, McInnes, Iain B, Kirkham, Bruce W, Sherlock, Jonathan, Moots, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788885/
https://www.ncbi.nlm.nih.gov/pubmed/31278139
http://dx.doi.org/10.1136/annrheumdis-2019-215356
_version_ 1783458543011102720
author McGonagle, Dennis G
McInnes, Iain B
Kirkham, Bruce W
Sherlock, Jonathan
Moots, Robert
author_facet McGonagle, Dennis G
McInnes, Iain B
Kirkham, Bruce W
Sherlock, Jonathan
Moots, Robert
author_sort McGonagle, Dennis G
collection PubMed
description Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. This is best highlighted by the significant clinical efficacy shown with inhibitors of IL-17A in treating axSpA and PsA. Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations. In this review, we focus on the latest data from studies investigating the role of IL-17A in ankylosing spondylitis (AS) and PsA that build on existing and emerging scientific knowledge in the field. Key remaining research questions are also highlighted to guide future research.
format Online
Article
Text
id pubmed-6788885
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67888852019-10-25 The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies McGonagle, Dennis G McInnes, Iain B Kirkham, Bruce W Sherlock, Jonathan Moots, Robert Ann Rheum Dis Review Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. This is best highlighted by the significant clinical efficacy shown with inhibitors of IL-17A in treating axSpA and PsA. Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations. In this review, we focus on the latest data from studies investigating the role of IL-17A in ankylosing spondylitis (AS) and PsA that build on existing and emerging scientific knowledge in the field. Key remaining research questions are also highlighted to guide future research. BMJ Publishing Group 2019-09 2019-07-05 /pmc/articles/PMC6788885/ /pubmed/31278139 http://dx.doi.org/10.1136/annrheumdis-2019-215356 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
McGonagle, Dennis G
McInnes, Iain B
Kirkham, Bruce W
Sherlock, Jonathan
Moots, Robert
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title_full The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title_fullStr The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title_full_unstemmed The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title_short The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
title_sort role of il-17a in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788885/
https://www.ncbi.nlm.nih.gov/pubmed/31278139
http://dx.doi.org/10.1136/annrheumdis-2019-215356
work_keys_str_mv AT mcgonagledennisg theroleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT mcinnesiainb theroleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT kirkhambrucew theroleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT sherlockjonathan theroleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT mootsrobert theroleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT mcgonagledennisg roleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT mcinnesiainb roleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT kirkhambrucew roleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT sherlockjonathan roleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies
AT mootsrobert roleofil17ainaxialspondyloarthritisandpsoriaticarthritisrecentadvancesandcontroversies